PLSE Quote, Financials, Valuation and Earnings

NeuroOne Medical Technologies has a net margin of -- compared to Pulse Biosciences's net margin of 54.53%. Pulse Biosciences's return on equity of -- beat NeuroOne Medical Technologies's return on equity of -238.93%.

Pulse Biosciences has a consensus price target of --, signalling downside risk potential of -72.08%. On the other hand NeuroOne Medical Technologies has an analysts' consensus of -- which suggests that it could grow by 206.75%. Given that NeuroOne Medical Technologies has higher upside potential than Pulse Biosciences, analysts believe NeuroOne Medical Technologies is more attractive than Pulse Biosciences.

Pulse Biosciences has a beta of 1.874, which suggesting that the stock is 87.435% more volatile than S&P 500. In comparison NeuroOne Medical Technologies has a beta of 0.692, suggesting its less volatile than the S&P 500 by 30.823%.

Pulse Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NeuroOne Medical Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pulse Biosciences pays -- of its earnings as a dividend. NeuroOne Medical Technologies pays out -- of its earnings as a dividend.

Pulse Biosciences quarterly revenues are --, which are smaller than NeuroOne Medical Technologies quarterly revenues of $3.3M. Pulse Biosciences's net income of -$10.1M is lower than NeuroOne Medical Technologies's net income of $1.8M. Notably, Pulse Biosciences's price-to-earnings ratio is -- while NeuroOne Medical Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pulse Biosciences is -- versus 3.23x for NeuroOne Medical Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Nutriband has a net margin of -- compared to Pulse Biosciences's net margin of -211%. Pulse Biosciences's return on equity of -- beat Nutriband's return on equity of -69.58%.

Pulse Biosciences has a consensus price target of --, signalling downside risk potential of -72.08%. On the other hand Nutriband has an analysts' consensus of $13.00 which suggests that it could grow by 144.36%. Given that Nutriband has higher upside potential than Pulse Biosciences, analysts believe Nutriband is more attractive than Pulse Biosciences.

Pulse Biosciences has a beta of 1.874, which suggesting that the stock is 87.435% more volatile than S&P 500. In comparison Nutriband has a beta of 1.049, suggesting its more volatile than the S&P 500 by 4.944%.

Pulse Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nutriband offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pulse Biosciences pays -- of its earnings as a dividend. Nutriband pays out -- of its earnings as a dividend.

Pulse Biosciences quarterly revenues are --, which are smaller than Nutriband quarterly revenues of $645.8K. Pulse Biosciences's net income of -$10.1M is lower than Nutriband's net income of -$1.4M. Notably, Pulse Biosciences's price-to-earnings ratio is -- while Nutriband's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pulse Biosciences is -- versus 26.08x for Nutriband. Usually stocks with elevated PS ratios are considered overvalued.

enVVeno Medical has a net margin of -- compared to Pulse Biosciences's net margin of --. Pulse Biosciences's return on equity of -- beat enVVeno Medical's return on equity of --.

Pulse Biosciences has a consensus price target of --, signalling downside risk potential of -72.08%. On the other hand enVVeno Medical has an analysts' consensus of $16.50 which suggests that it could grow by 503.29%. Given that enVVeno Medical has higher upside potential than Pulse Biosciences, analysts believe enVVeno Medical is more attractive than Pulse Biosciences.

Pulse Biosciences has a beta of 1.874, which suggesting that the stock is 87.435% more volatile than S&P 500. In comparison enVVeno Medical has a beta of 1.040, suggesting its more volatile than the S&P 500 by 3.991%.

Pulse Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. enVVeno Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pulse Biosciences pays -- of its earnings as a dividend. enVVeno Medical pays out -- of its earnings as a dividend.

Pulse Biosciences quarterly revenues are --, which are smaller than enVVeno Medical quarterly revenues of --. Pulse Biosciences's net income of -$10.1M is lower than enVVeno Medical's net income of -$6.2M. Notably, Pulse Biosciences's price-to-earnings ratio is -- while enVVeno Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pulse Biosciences is -- versus 251.08x for enVVeno Medical. Usually stocks with elevated PS ratios are considered overvalued.

SINTX Technologies has a net margin of -- compared to Pulse Biosciences's net margin of -882.81%. Pulse Biosciences's return on equity of -- beat SINTX Technologies's return on equity of -148.9%.

Pulse Biosciences has a consensus price target of --, signalling downside risk potential of -72.08%. On the other hand SINTX Technologies has an analysts' consensus of $30.00 which suggests that it could grow by 1062.79%. Given that SINTX Technologies has higher upside potential than Pulse Biosciences, analysts believe SINTX Technologies is more attractive than Pulse Biosciences.

Pulse Biosciences has a beta of 1.874, which suggesting that the stock is 87.435% more volatile than S&P 500. In comparison SINTX Technologies has a beta of 1.124, suggesting its more volatile than the S&P 500 by 12.355%.

Pulse Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. SINTX Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pulse Biosciences pays -- of its earnings as a dividend. SINTX Technologies pays out -- of its earnings as a dividend.

Pulse Biosciences quarterly revenues are --, which are smaller than SINTX Technologies quarterly revenues of $192K. Pulse Biosciences's net income of -$10.1M is lower than SINTX Technologies's net income of -$1.7M. Notably, Pulse Biosciences's price-to-earnings ratio is -- while SINTX Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pulse Biosciences is -- versus 1.61x for SINTX Technologies. Usually stocks with elevated PS ratios are considered overvalued.